GMP Manufacturing

GMP制造

• 批准号: 10242158
• 负责人: LARRY W KWAK
• 金额: $ 23.32万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-02 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10242158
• 关键词: Ablation; Agonist; Antibody Formation; Autologous; Biological; Biopolymers; CD19 gene; Cell Therapy; Cells; Chelating Agents; Chemicals; Cities; City of Hope Comprehensive Cancer Center; Clinical; Clinical Research; Clinical Trials; Code; Complex; Country; Cytomegalovirus; Cytomegalovirus Vaccines; DNA; DNA Binding; Development; Diamond; Ensure; Epidermal Growth Factor Receptor; Europe; Funding; Genetic; Goals; Human; Hybrids; IL2RA gene; Infrastructure; Investigational Drugs; Investigational New Drug Application; Laboratories; Lentivirus; Lentivirus Vector; Lymphoma; Methods; Monoclonal Antibodies; Morbidity - disease rate; Natural Products; Patients; Peptides; Pharmaceutical Preparations; Phase I Clinical Trials; Preparation; Process; Production; Quality Control; Recording of previous events; Regulatory Affairs; Research Personnel; Resource Sharing; Resources; STAT3 gene; Safety; Seeds; Small Interfering RNA; System; T-Lymphocyte; Testing; Therapeutic; Toxicology; Training; Translations; United States Food and Drug Administration; Vaccine Production; Vaccines; Viral; aptamer; basiliximab; chimeric antigen receptor; chimeric antigen receptor T cells; clinical lot; drug development; experience; gene therapy; innovation; manufacturing facility; mortality; nanomaterials; nonhuman primate; novel therapeutics; operation; phase 1 study; phase 2 study; pre-clinical; preclinical development; preclinical study; product development; quality assurance; small molecule; therapeutic gene; vaccine-induced antibodies

SUMMARY Over a decade ago, City of Hope (COH) recognized the need to establish the infrastructure necessary to allow researchers to efficiently and effectively develop emerging cell and gene therapeutic innovations through pre- clinical and clinical studies. To achieve this goal, COH created the Biological and Cellular GMP Manufacturing Shared Resource and the Office of IND Development and Regulatory Affairs and two current Good Manufacturing Practice (cGMP)-compliant biologics manufacturing facilities, the Center for Biomedicine and Genetics (CBG) and the Cell Therapy Production Center (CTPC). More recently, COH expanded this translational infrastructure by creating a separate small molecule cGMP-compliant manufacturing facility, the Chemical GMP Synthesis Facility (CGSF). An independently managed Quality Systems group provides QA oversight to all manufacturing and product Quality Control activities and is responsible for regulatory compliance and product release of all cGMP products manufactured at COH. COH established the Biological and Cellular GMP Manufacturing Shared Resource and the CGSF to be not only facilitating resources for COH researchers, but also regional and national resources to facilitate the rapid translation of new ideas that could benefit patients across the nation. With over 16 years of operation and a combined staff of over 60, the Biological and Cellular GMP Manufacturing Shared Resource and CGSF have provided over 300 released lots of cell therapies, biologics, and small molecules to over 40 investigators at COH and across the country and Europe. The primary objective of Core D is to provide process development, regulatory support, and well- documented cGMP-compliant clinical-grade production of characterized CAR T cell products, monoclonal antibodies (mAb), lentivirus vectors, and complex small molecules, including nanomaterials, biopolymers (peptides, siRNA-aptamers, and DNA-peptide hybrids), and complex natural products. We will apply our established project management, product development, regulatory, and manufacturing capability to the benefit of COH SPORE investigators by providing assistance in pre-clinical development strategy, regulatory affairs, and process devolvement. Quality Assurance, product characterization, and compliance with regulatory requirements for process and product gained from our extensive history of cGMP manufacturing for clinical trials will ensure suitability, control, and scalability of the proposed clinical projects.

总结 十多年前，希望之城（COH）认识到需要建立必要的基础设施， 研究人员通过预处理，有效地开发新兴的细胞和基因治疗创新， 临床和临床研究。为了实现这一目标，COH创建了生物和细胞GMP制造 共享资源和IND开发和法规事务办公室以及两个当前良好的 符合生产规范（cGMP）的生物制剂生产设施，生物医学中心和 遗传学（CBG）和细胞治疗生产中心（CTPC）。最近，COH扩大了这一点， 通过创建单独的小分子cGMP合规生产设施， 化学GMP合成设施（CGSF）。独立管理的质量体系小组提供QA 监督所有制造和产品质量控制活动，并负责监管 COH生产的所有cGMP产品的合规性和产品放行。COH建立了生物 和细胞GMP生产共享资源和CGSF不仅是促进COH的资源， 研究人员，但也有区域和国家资源，以促进新的想法， 造福全国各地的患者。拥有超过16年的经营和超过60名员工， 生物和细胞GMP生产共享资源和CGSF提供了300多个放行批次 向COH和全国各地的40多名研究人员提供细胞疗法，生物制剂和小分子， 欧洲核心D的主要目标是提供工艺开发、监管支持，以及 记录的符合cGMP的临床级生产的特征性CAR T细胞产品，单克隆 抗体（mAb）、慢病毒载体和复杂小分子，包括纳米材料、生物聚合物 （肽、siRNA-适体和DNA-肽杂合体）和复杂的天然产物。我们将应用我们的 建立项目管理、产品开发、监管和制造能力， COH SPORE研究者通过在临床前开发策略、法规事务、 和过程的演变。质量保证、产品表征和法规遵从性 从我们广泛的临床cGMP生产历史中获得的工艺和产品要求 试验将确保拟议的临床项目的适用性、可控性和可扩展性。